Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.
A group of 15 cats experimentally infected with a Swiss isolate of feline immunodeficiency virus (FIV) and a group of 15 FIV-negative control cats were inoculated with an FeLV vaccine containing recombinant FeLV-envelope. High ELISA antibody titer developed after vaccination in FIV-positive and FIV-negative cats. Vaccinated and nonvaccinated controls were later challenge exposed by intraperitoneal administration of virulent FeLV subtype A (Glasgow). Although 12 of 12 nonvaccinated controls became infected with FeLV (10 persistently, 2 transiently), only 1 of 18 vaccinated (9 FIV positive, 9 FIV negative) cats had persistent and 2 of 18 had transient viremia. From these data and other observations, 2 conclusions were drawn: In the early phase of FIV infection, the immune system is not depressed appreciably, and therefore, cats may be successfully immunized; a recombinant FeLV vaccine was efficacious in protecting cats against intraperitoneal challenge exposure with FeLV.
Lehmann
R
R
Department of Medicine, School of Veterinary Medicine, University of Zurich, Switzerland.
Franchini
M
M
Aubert
A
A
Wolfensberger
C
C
Cronier
J
J
Lutz
H
H
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002415:Cats; D004797:Enzyme-Linked Immunosorbent Assay; D016181:Feline Acquired Immunodeficiency Syndrome / Q000276:immunology*; D005260:Female; D007117:Immunization, Secondary / Q000662:veterinary; D016089:Immunodeficiency Virus, Feline; D005256:Leukemia Virus, Feline / Q000276:immunology*; D016582:Leukemia, Feline / Q000517:prevention & control*; D008297:Male; D015682:Retroviridae Proteins, Oncogenic / Q000276:immunology; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination / Q000662:veterinary; D014614:Vaccines, Synthetic / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology; D014766:Viremia / Q000517:prevention & control / Q000662:veterinary
D000914:Antibodies, Viral; D015682:Retroviridae Proteins, Oncogenic; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; C045569:feline leukemia virus vaccine